Clinical Trial Update: Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the pharmacokinetic profile of two PB1023 formulations after a single subcutaneous injection in adults with Type 2 diabetes mell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PB1023

Snippet

Sponsor: PhaseBio Pharmaceuticals Inc. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED